美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · ADMA近 30 天 5 則 · 第 1 / 1 頁
- Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
- Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
- Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know
- Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
- Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?
- ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness
- ADMA Biologics Inc (ADMA) (Q2 2026) Earnings Call Highlights: Ascentiv Surges 24% as Gross ...
- ADMA Biologics Q2 Earnings Call Highlights
- ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
- Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
- Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?
- ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
- Adma Biologics (ADMA) Rises Higher Than Market: Key Facts
- ADMA Biologics (ADMA) Faces Class Actions And Probes Over Revenue Allegations
- ADMA Biologics (ADMA) Stock Looks Undervalued Even After A 5 Year Run
- Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。